Sector: Health Care
BIOMARIN PHARMACEUTICAL INC · Meeting: June 2, 2026
Directors FOR
5
Directors AGAINST
5
Say on Pay
FOR
Auditor
FOR
Election of Directors
Against Analysis
Ms. Anderson has served since July 2019, giving her full tenure overlap with BioMarin's severe stock underperformance — the stock fell 45.5% over three years while the company's own disclosed peer group gained a median of 30.8%, a gap of 76.3 percentage points that far exceeds the 20-point trigger; a five-year check does not rescue the vote as the five-year gap versus the peer median is similarly severe (-75.6pp); additionally, she failed to meet the 75% meeting attendance threshold in 2025.
Mr. Clark currently sits on five other public company boards in addition to BioMarin — Takeda Pharmaceutical, Olema Pharmaceuticals, Kyverna Therapeutics, Corvus Pharmaceuticals, and Guardant Health — well above the four-board maximum for non-executive directors under the policy; although Takeda retirement is planned for June 2026, at the time of the meeting he exceeds the limit; he also failed the 75% attendance threshold in 2025 due to pre-existing scheduling conflicts, making a FOR vote inappropriate despite the company's stated confidence in his engagement.
Dr. Dere has served since July 2016, giving him full overlap with BioMarin's significant stock decline; over three years the stock fell 45.5% while the company's peer group gained a median of 30.8%, a gap of 76.3 percentage points far exceeding the 20-point trigger for directors whose company has posted a negative absolute return; the five-year check (peer gap of -75.6pp) does not mitigate the vote, confirming sustained rather than transient underperformance.
Dr. Ho has served since February 2021, giving her substantial tenure overlap with the three-year underperformance period; BioMarin's stock fell 45.5% while its disclosed peer group posted a median gain of 30.8%, a gap of 76.3 percentage points that far exceeds the 20-point trigger; the five-year gap (-75.6pp vs peers) does not provide a mitigant, confirming the underperformance is sustained.
Mr. Hombach has served since September 2017, giving him full overlap with the underperformance period; BioMarin's stock declined 45.5% over three years against a peer group median gain of 30.8%, a gap of 76.3 percentage points far exceeding the policy trigger; the five-year check confirms the underperformance is sustained rather than a temporary dip, supporting a consistent AGAINST vote.
For Analysis
Ms. Bodem joined in December 2023, which is within 24 months of the 2026 annual meeting, making her exempt from the TSR underperformance trigger under the new-director exemption; she brings relevant financial expertise as a former public-company CFO and meets all other policy criteria.
Dr. Countouriotis joined in December 2023, placing her within the 24-month new-director exemption window and shielding her from the TSR trigger; she is a sitting CEO of a private company (Avenzo Therapeutics), and her two outside public board seats (Iovance, Passage Bio) do not exceed any policy limit.
Mr. Enyedy joined in December 2023, placing him within the 24-month new-director exemption and shielding him from the TSR trigger; he holds two outside public board seats and brings relevant biotech executive experience.
Mr. Hardy joined as CEO and director in December 2023, placing him within the 24-month new-director exemption from the TSR trigger; as the sitting CEO he is the executive responsible for executing the turnaround strategy, and the TSR exemption appropriately allows him reasonable time to demonstrate results before being held accountable.
Mr. Walbert joined in February 2025, which is within 24 months of the 2026 annual meeting date, making him exempt from the TSR underperformance trigger under the new-director exemption; he brings relevant rare-disease and biotech CEO experience.
BioMarin's stock has fallen 45.5% over three years while its own disclosed compensation peer group gained a median of 30.8% — a gap of 76.3 percentage points that far exceeds the policy's 20-point trigger for companies with negative absolute TSR. Four long-tenured directors (Anderson, Dere, Ho, Hombach) are voted AGAINST for full tenure overlap with this sustained underperformance, confirmed by the five-year check. Ian Clark is voted AGAINST for overboarding (five outside public company seats) and sub-75% attendance. Five directors with tenures within the 24-month new-director exemption window (Bodem, Countouriotis, Enyedy, Hardy, Walbert) receive FOR votes.
CEO
Alexander Hardy
Total Comp
$21,927,563
Prior Support
93%%
The CEO's total compensation of approximately $21.9 million is substantial but the pay structure is strongly performance-oriented: 93% of pay is variable and at-risk, 70% is tied to explicit performance conditions, and the long-term equity program uses multi-year relative TSR, revenue growth, and operating margin metrics — the right kinds of measures for a biotech company; the long-term performance awards for the 2023–2025 period actually paid out below target (69.4% for relative TSR, 53.3% for operating margin) because performance conditions were not met, demonstrating that the incentive structure is functioning as intended and executives do not simply collect maximum awards regardless of results. The prior year Say on Pay received 93% support, well above the 70% threshold, and no governance concerns such as missing clawback policies or excessive fixed pay are present.
Auditor
KPMG LLP
Tenure
24 yrs
Audit Fees
$4,191,625
Non-Audit Fees
$343,071
Non-audit fees (tax fees of $44,899 plus other fees of $298,172, totaling $343,071) represent approximately 8.2% of audit fees of $4,191,625, well below the 50% threshold that would trigger a concern about auditor independence; KPMG's tenure of approximately 24 years (since June 2002) is just below the 25-year trigger; KPMG is a Big 4 firm appropriate for a $10.5 billion market cap company; no material financial restatements are disclosed.
BioMarin's 2026 annual meeting is dominated by a serious stock performance problem: the company's shares have lost 45.5% over three years while its own disclosed peer group gained a median of 30.8%, triggering AGAINST votes for five of ten director nominees based on tenure overlap with that underperformance. The auditor and Say on Pay proposals both pass policy screens — KPMG's non-audit fees are well within acceptable limits, and the executive compensation program is genuinely performance-linked with below-target long-term payouts reflecting actual underperformance.
14 companies disclosed in 2026 proxy filing
